Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The influence of microorganisms in allergic diseases.
Tortajada-Girbés M, Torres-Borrego J. Tortajada-Girbés M, et al. Allergol Immunopathol (Madr). 2017 Nov-Dec;45(6):519-520. doi: 10.1016/j.aller.2017.10.001. Allergol Immunopathol (Madr). 2017. PMID: 29110881 No abstract available.
Omalizumab: just what we needed.
Torres-Borrego J. Torres-Borrego J. Allergol Immunopathol (Madr). 2014 Jan-Feb;42(1):1-2. doi: 10.1016/j.aller.2014.01.001. Allergol Immunopathol (Madr). 2014. PMID: 24529608 No abstract available.
[Consensus-based approach for severe paediatric asthma in routine clinical practice].
Plaza AM, Ibáñez MD, Sánchez-Solís M, Bosque-García M, Cabero MJ, Corzo JL, García-Hernández G, de la Hoz B, Korta-Murua J, Sánchez-Salguero C, Torres-Borrego J, Tortajada-Girbés M, Valverde-Molina J, Zapatero L, Nieto A. Plaza AM, et al. An Pediatr (Barc). 2016 Feb;84(2):122.e1-122.e11. doi: 10.1016/j.anpedi.2015.08.015. Epub 2015 Oct 26. An Pediatr (Barc). 2016. PMID: 26515042 Free article. Spanish.
Efficacy and effectiveness of omalizumab in the treatment of childhood asthma.
Tortajada-Girbés M, Bousquet R, Bosque M, Carrera Martínez JJ, Ibáñez MD, Moreira A, Nieto A, Plaza AM, Rivas C, Requena G, Sánchez-Solis M, Tabar A, Torres-Borrego J, Zapatero L. Tortajada-Girbés M, et al. Among authors: torres borrego j. Expert Rev Respir Med. 2018 Sep;12(9):745-754. doi: 10.1080/17476348.2018.1507740. Epub 2018 Aug 28. Expert Rev Respir Med. 2018. PMID: 30141696 Review.
Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma.
Nieto García A, Garriga-Baraut T, Plaza Martín AM, Nieto Cid M, Torres Borrego J, Folqué Giménez MDM, Lozano Blasco J, Bosque García M, Moreno-Galarraga L, Tortajada-Girbés M, Rivas Juesas C, Penín Antón M, Caballero-Rabasco MA, Gaboli M, López Neyra A, Navarro Morón J, Freixa Benavente A, Valdesoiro Navarrete L, Ballester Asensio E, Sanz Santiago V, Romero García R, Gimeno Díaz de Atauri Á, Valenzuela Soria A, Sánchez Mateos M, Batlles Garrido J, Andrés Martín A, Campos Alonso E, Aragón Fernández C, Vázquez Rodríguez E, Martínez Pardo L, Del-Río Camacho G, Mazón Ramos Á. Nieto García A, et al. Among authors: torres borrego j. Pediatr Allergy Immunol. 2021 Jul;32(5):980-991. doi: 10.1111/pai.13484. Epub 2021 Mar 20. Pediatr Allergy Immunol. 2021. PMID: 33619748
36 results